Markets

Nova Mentis appoints renowned neuroscientist to the advisory board – columns

Nova Mentis Life Science (CSE NOVA / FSE HN3Q) is dedicated to the extremely exciting and currently very popular sector of psychedelic drugs. Among other things, the focus is on researching the effect of the active ingredient psilocybin on expressions of the autistic spectrum. For this one has the support of Dr. Julia V. Perederiy, who is a member of the company’s scientific advisory board.

And Dr. Perederiy’s expertise matches the company’s needs very closely. She is a specialist in early-stage technologies and data-driven corporate strategy and has both scientific and commercialization expertise in biological innovation from the analysis of single cells to systemic therapies.

Dr. Marvin Hausman, Chair of the Nova Mentis Scientific Advisory Board, sees Dr. Perederiy is an established, research-oriented neuroscientist whose knowledge will be invaluable in the upcoming preclinical study of the treatment of ASD (autism spectrum disorder) with psilocybin. This study should allow Nova Mentis to determine the therapeutic dosage of psilocybin for use in future human trials.

Dr. Perederiy is the author of numerous peer-reviewed publications, including studies of great influence on brain plasticity in neurodegeneration and the neurogenetics of autism, according to today’s press release. In addition, the expert is an experienced entrepreneur and management consultant who supports biotechnology companies with business planning, market research and financing.

The new addition to Nova Menti’s Scientific Advisory Board holds bachelor’s degrees in neurobiology and psychology from the University of California, Berkeley, a master’s degree in technology entrepreneurship from the University of Portland, and a PhD in neuroscience from Oregon Health & Science University.

As I said, Dr. Perederiy, due to her qualifications, will be exactly the woman that Nova Mentis next to Dr. Hausman needs to successfully develop what we believe to be a promising research approach. We will continue to report!

Subscribe to our free newsletter: https://goldinvest.de/newsletter
Visit us on Twitter: https://twitter.com/GOLDINVEST_de

Risk warning: GOLDINVEST Consulting GmbH offers editors, agencies and companies the opportunity to publish comments, analyzes and news on www.goldinvest.de. This content is intended solely for the information of the reader and does not represent any kind of call for action, neither explicitly nor implicitly are they to be understood as a guarantee of possible price developments. Furthermore, they are in no way a substitute for individual, expert investment advice, rather they are advertising / journalistic texts. Readers who make investment decisions or carry out transactions on the basis of the information provided here act entirely at their own risk. The acquisition of securities involves high risks, which can lead to the total loss of the capital invested. GOLDINVEST Consulting GmbH and its authors expressly exclude any liability for financial losses or the content-related guarantee for topicality, correctness, appropriateness and completeness of the articles offered here. Please take note of our Terms of Use.

In accordance with Section 34b WpHG and Section 48f Paragraph 5 BörseG (Austria), we would like to point out that partners, authors and / or employees of GOLDINVEST Consulting GmbH can hold shares in Nova Mentis Life Sciences and thus a conflict of interest could exist. We cannot rule out that other stock market letters, media or research firms will discuss the values ​​we have discussed during the same period. Therefore, symmetrical generation of information and opinions can occur during this period. Furthermore, there is a consulting or other service contract between GOLDINVEST Consulting GmbH and a third party in the issuer’s warehouse (Nova Mentis Life Sciences), which creates a conflict of interest, especially since this third party is GOLDINVEST Consulting GmbH for a fee for reporting paid to Nova Mentis Life Sciences. This third party can also hold, sell or buy shares in the issuer and would thus benefit from an increase in the price and the trading volume in the shares of Nova Mentis Life Sciences. This is another conflict of interest.

Note:
PERSONAL-FINANCIAL.COM publishes analyzes, columns and news from various sources in this section. PERSONAL-FINANCIAL.COM AG is not responsible for content that is recognizably posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Tags

Related Articles

Back to top button
Close
Close